Johnson & Johnson Appoints Ryan Koors as VP IR, Highlights 64-Year Dividend Record
JNJ•Johnson & Johnson appointed Ryan Koors as Vice President, Investor Relations, effective May 7, 2026, succeeding Darren Snellgrove who left to become CFO of Halozyme. The company was also highlighted as one of three healthcare stocks for long-term wealth building, citing its focus on pharmaceuticals and medtech with strong sales growth and a 64-year dividend history.
1. Executive Appointment
Ryan Koors will assume the role of Vice President, Investor Relations at Johnson & Johnson on May 7, 2026, reporting to EVP and CFO Joseph J. Wolk. He succeeds Darren Snellgrove, who has departed to become CFO of Halozyme, and brings over 20 years of strategic financial leadership across Innovative Medicine, MedTech and Supply Chain.
2. Wealth-Building Recommendation
Johnson & Johnson was named among three healthcare stocks for real wealth building, with analysts pointing to its strong pharmaceuticals and medtech sales growth. The company’s uninterrupted 64-year dividend streak was cited as a key factor supporting its appeal for long-term income investors.
